Drug
Alks 7290
Alks 7290: highest development phase Phase 2, developed by Alkermes. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 7290 NCT07755410 | Phase 2 | Attention Deficit Disorder With Hyperactivity (ADHD) |
Latest
No recent events.
Follow Alks 7290 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.